Literature DB >> 15630746

Successful treatment of long-standing neuro-Behçet's disease with infliximab.

Haroon Sarwar1, Hugh McGrath, Luis R Espinoza.   

Abstract

Behçet's disease is a chronic relapsing form of vasculitis affecting multiple organs. Central nervous system involvement is a common presentation. Tumor necrosis factor-alpha (TNF-alpha) is considered to play a major role in the disease pathogenesis. We describe a patient with a long history of neuro-Behçet's disease who showed a remarkable response to infliximab therapy. Given the variable and limited success of other interventions, the use of anti-TNF-alpha therapy seems to be effective for patients with refractory disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15630746

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  14 in total

1.  Successful treatment of refractory neuro-Behcet's disease with infliximab: a case report to show its efficacy by magnetic resonance imaging, transcranial magnetic stimulation and cytokine profile.

Authors:  K Fujikawa; K Aratake; A Kawakami; T Aramaki; N Iwanaga; Y Izumi; K Arima; M Kamachi; M Tamai; M Huang; H Nakamura; Y Nishiura; T Origuchi; H Ida; K Eguchi
Journal:  Ann Rheum Dis       Date:  2007-01       Impact factor: 19.103

2.  Successful treatment of rheumatoid meningitis with cyclophosphamide but not infliximab.

Authors:  R C Chou; J W Henson; D Tian; E T Hedley-Whyte; A M Reginato
Journal:  Ann Rheum Dis       Date:  2006-08       Impact factor: 19.103

3.  Late response to anti-TNF-α therapy in refractory mucocutaneous lesions of Behçet's disease.

Authors:  Nádia Emi Aikawa; Carla Gonçalves; Clovis Artur Almeida Silva; Célio Gonçalves; Eloísa Bonfá; Jozélio Freire de Carvalho
Journal:  Rheumatol Int       Date:  2009-12-11       Impact factor: 2.631

4.  Infliximab in the treatment of rheumatoid meningoencephalitis.

Authors:  Felix Luessi; Janina Sollors; Harald Müller; Peter Stoeter; Clemens Sommer; Thomas Vogt; Frank Birklein; Frank Thömke
Journal:  J Neurol       Date:  2009-12       Impact factor: 4.849

Review 5.  Update on the therapy of Behçet disease.

Authors:  Zeinab Saleh; Thurayya Arayssi
Journal:  Ther Adv Chronic Dis       Date:  2014-05       Impact factor: 5.091

6.  Pulmonary aneurysms and intracardiac thrombi due to Behçet's disease in an African-American adolescent with oculocutaneous albinism.

Authors:  Lois M Endo; Steven M Rowe; Robb L Romp; Mark A Buckmaster; T Prescott Atkinson
Journal:  Clin Rheumatol       Date:  2006-09-19       Impact factor: 2.980

Review 7.  Neuro-Behçet's syndrome: differential diagnosis and management.

Authors:  Erdal Diri; Louis R Espinoza
Journal:  Curr Rheumatol Rep       Date:  2006-08       Impact factor: 4.592

Review 8.  Behçet syndrome: from pathogenesis to novel therapies.

Authors:  Gianluigi Mazzoccoli; Angela Matarangolo; Rosa Rubino; Michele Inglese; Angelo De Cata
Journal:  Clin Exp Med       Date:  2014-12-02       Impact factor: 3.984

Review 9.  Infliximab for patients with neuro-Behcet's disease: case series and literature review.

Authors:  Afshin Borhani Haghighi; Anahid Safari; Mohammad Ali Nazarinia; Zahra Habibagahi; Saeedeh Shenavandeh
Journal:  Clin Rheumatol       Date:  2011-03-24       Impact factor: 2.980

Review 10.  The spectrum of nervous system involvement in Behçet's syndrome and its differential diagnosis.

Authors:  Aksel Siva; Sabahattin Saip
Journal:  J Neurol       Date:  2009-04-27       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.